Zacks: Brokerages Set $5.50 Target Price for AEterna Zentaris Inc. (NASDAQ:AEZS)
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus price objective of $5.50 for the company and are anticipating that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 62 out of 256 based on the ratings given to related companies.
Several equities analysts have recently weighed in on AEZS shares. ValuEngine upgraded China Southern Airlines from a “sell” rating to a “hold” rating in a report on Tuesday, June 11th. TheStreet upgraded SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a report on Thursday, June 13th. Finally, Zacks Investment Research cut KKR & Co Inc from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.
AEZS stock traded up $0.21 during midday trading on Friday, reaching $2.83. The stock had a trading volume of 45,303 shares, compared to its average volume of 113,618. The business’s fifty day moving average price is $2.81. The company has a market capitalization of $44.31 million, a price-to-earnings ratio of 11.32 and a beta of 1.25. AEterna Zentaris has a twelve month low of $1.29 and a twelve month high of $5.57.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.18). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $4.20 million. AEterna Zentaris had a negative net margin of 666.76% and a negative return on equity of 328.95%. Sell-side analysts expect that AEterna Zentaris will post 1.71 EPS for the current fiscal year.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Further Reading: Compound Interest and Why It Matters When Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.